Hoffman et al. (2019) [15]
|
USA
|
Cohort
|
23/35
|
16/16
|
48.5/53.4
|
52.5/52.5
|
MIDLF/TLIF
|
1, 2, 3, 4, 5, 6, 8, 9
|
Marengo et al. (2018) [16]
|
Italy
|
Cohort
|
20/20
|
12/9
|
45.75/54
|
12/12
|
PLIF/PLIF
|
1, 2, 3, 4, 6, 8, 9, 10
|
Lee and Ahn (2017) [17]
|
Korea
|
RCT
|
35/37
|
31/33
|
51.2/51.7
|
24/24
|
PLIF/PLIF
|
4, 5, 6, 9, 10
|
Takenaka et al. (2017) [18]
|
Japan
|
Cohort
|
42/77
|
18/31
|
65.8/66.0
|
17/35.4
|
PLIF/PLIF
|
1, 2, 4, 5, 8, 9, 10
|
Sakaura et al. (2017) [19]
|
Japan
|
Cohort
|
22/20
|
4/6
|
70.7/68.3
|
39/35
|
PLIF/PLIF
|
1, 2, 7, 8, 9, 10
|
Peng et al. (2017) [20]
|
China
|
Cohort
|
51/46
|
23/21
|
62.8/61.9
|
12/12
|
PLIF/PLIF
|
1, 2, 3, 6, 8, 9, 10
|
Sakaura et al. (2016) [21]
|
Japan
|
Cohort
|
95/82
|
46/36
|
68.7/67.0
|
39/35
|
PLIF/PLIF
|
1, 2, 7, 8, 9, 10
|
Orita et al. (2016) [22]
|
Japan
|
Cohort
|
20/20
|
11/12
|
63.5/63.7
|
12/12
|
TLIF/TLIF
|
1, 2
|
Hung et al. (2016) [14]
|
China
|
Cohort
|
16/16
|
6/5
|
60.37/63.12
|
18/18
|
PLIF/PLIF
|
1, 2, 3, 4, 5, 6, 7
|
Ninomiya et al. (2016) [23]
|
Japan
|
Cohort
|
11/10
|
7/5
|
62.2/61.4
|
12/12
|
PLIF/PLIF
|
9
|
Chin et al. (2016) [24]
|
USA
|
Cohort
|
30/30
|
18/15
|
48/62
|
24/24
|
NM/NM
|
1, 2, 4, 5, 6
|
Lee et al. (2015) [13]
|
Korea
|
RCT
|
38/39
|
33/34
|
51.3/51.9
|
12/12
|
PLIF/PLIF
|
1, 2, 3, 4, 5, 6, 9, 10
|